Currently o ering: 100k
OUR TEAM
Daniel Oliver Founder & CEO
LEAD INVESTOR – Ian Tomlinson
Laura Ferguson UK Director
Current chairman at the Stevenage Bioscience Catalyst & Investment Committee at the £40M Apollo Therapeutics fund.
Joan Marcos General Manager
Other professional experience includes: MRC Laboratory of Molecular Biology; co-founder Domantis, and VP & director Global BD atGSK. Life sciences collaboration with Astrazeneca, GSK, J&J, Imperial College, UCL and the University of Cambridge.
INVESTMENT OPPORTUNITY SHEET COMPANY: Capital Cell WEB: www.capitalcell.net
2.36M
Currently o ering:
100k (total round size:
Jo Slota-Newson Director of Operations
PROBLEM
SECTOR: Equity crowdfunding PRE-MONEY VALUATION:
Cameron Coles Director of Strategy & Finance
800K)
THE PROJECT
SOLUTION Our VISION: THE life sciences funding platform What makes us special? The only UK life science equity platform The only pan-European life science platform Operational hub in Barcelona, Spain combined with a business development presence located in Cambridge, UK, the biotech hub of Europe
MARKET Globally, biotech and life sciences outperformed all the major stock market indexes from 2013-2015. Health technology is the most pro table investment sector in the USA. Biotech market worth $71bn in 2015. The equity crowdfunding market is expected to double in size annually and to become a $36bn global market by 2020. The equity crowdfunding market is forecast to overtake VCs as a source of funding in the Eurozone by 2020.
INVESTMENT PARAMETRERS Exit: 2021 Forecast EBITDA at exit: 7.6m EBITDA x: 5 times
Highly scalable, crowdsourcing at the core.
ROI: 1.510%
BUSINESS MODEL
Europe’s rst equity crowd funding platform specialising in life sciences, now expanding to the UK, Australia and Asia. 13 successful campaigns to date raising 4M from 720 + individual investors. Promoted the rst life science equity crowdfunding campaign to exceed southern Europe.
Limited investor access in highly lucrative Biotech sector due to large ticket sizes and requirement for technical expertise. Entrepreneurs spend excessive time fundraising & need for more seedstage nance. Generalist platforms lack credibility. or specialist knowledge Crowdfunding expertise blended with a life science grounding is limited, and the existing platforms, VC’s or Business Angel networks are simply not scalable
Pilar Puig Head Life Science Analyst & BEN Leader
1m in
Based on an exclusive & scalable system of expert investment analysis.
Capital Cell generates revenue from charging campaign fees as a % of total funds raised through the platform. In addition, as traction is gained in the UK, we expect to charge a campaign set-up fee payable regardless of the campaigns success plus carry income locked in by way of campaign agreements. Capital Cell is also growing the BioExpert Network which is a community of life science experts who analyse and provide feedback on all potential campaigns. This makes Capital Cell unique as we provide real “value add” to the entrepreneur bringing the campaign and we have plans to monetise this network.
WHAT NEXT
Forecast P&L
In the process of creating Capital Cell Australia/Asia in partnership with local capital group ces by end of 2017
2017
2018
2019
2020
2021
Revenue Campaign fees - cash Carry income Campaign set-up fees Expert network fees Total revenue
630.000
1.890.000
3.937.500
7.425.000
-
-
-
-
-
56.700
94.500
162.000
239.400
8.100 14.400 652.500
100.800
351.000
798.000
1.824.000
4.383.000
8.385.000
14.033.400
(176.400)
(529.200)
Gross profit
476.100
1.518.300
73%
11.970.000
2.047.500
Cost of sales
GP%
Launching in the UK market with FCA authorisation at end of April
Expecting headcount of 17 in Cambridge + Barcelona o INVEST HERE http://www.capitalcell.net/investment/capital-cell-uk75/ First UK campaigns already actively pitching
FORECAST FINANCIAL DATA
(1.102.500) 3.280.500
(2.079.000) 6.306.000
(3.351.600) 10.681.800
74%
75%
75%
76%
(1.000.771)
(1.344.785)
(1.739.117)
(2.007.478)
Overheads Staff Technology
(505.628) (72.500)
(74.750)
(97.175)
(126.328)
(164.226)
External services
(144.000)
(204.800)
(287.760)
(403.312)
(566.974)
General & admin
(129.586)
(182.892)
(217.783)
(271.816)
Total overheads
(851.713) (1.463.213) (1.947.503) (2.540.573)
EBITDA
(375.613)
EBITDA %
-79%
55.087 4%
1.332.997 41%
3.765.427 60%
(308.524) (3.047.202) 7.634.598 71%
Daniel Oliver Founder & CEO
LEAD INVESTOR – Ian Tomlinson
Laura Ferguson UK Director
Current chairman at the Stevenage Bioscience Catalyst & Investment Committee at the £40M Apollo Therapeutics fund.
Joan Marcos General Manager
Other professional experience includes: MRC Laboratory of Molecular Biology; co-founder Domantis, and VP & director Global BD atGSK. Life sciences collaboration with Astrazeneca, GSK, J&J, Imperial College, UCL and the University of Cambridge.
INVESTMENT OPPORTUNITY SHEET COMPANY: Capital Cell WEB: www.capitalcell.net
2.36M
Currently o ering:
100k (total round size:
Jo Slota-Newson Director of Operations
PROBLEM
SECTOR: Equity crowdfunding PRE-MONEY VALUATION:
Cameron Coles Director of Strategy & Finance
800K)
THE PROJECT
SOLUTION Our VISION: THE life sciences funding platform What makes us special? The only UK life science equity platform The only pan-European life science platform Operational hub in Barcelona, Spain combined with a business development presence located in Cambridge, UK, the biotech hub of Europe
MARKET Globally, biotech and life sciences outperformed all the major stock market indexes from 2013-2015. Health technology is the most pro table investment sector in the USA. Biotech market worth $71bn in 2015. The equity crowdfunding market is expected to double in size annually and to become a $36bn global market by 2020. The equity crowdfunding market is forecast to overtake VCs as a source of funding in the Eurozone by 2020.
INVESTMENT PARAMETRERS Exit: 2021 Forecast EBITDA at exit: 7.6m EBITDA x: 5 times
Highly scalable, crowdsourcing at the core.
ROI: 1.510%
BUSINESS MODEL
Europe’s rst equity crowd funding platform specialising in life sciences, now expanding to the UK, Australia and Asia. 13 successful campaigns to date raising 4M from 720 + individual investors. Promoted the rst life science equity crowdfunding campaign to exceed southern Europe.
Limited investor access in highly lucrative Biotech sector due to large ticket sizes and requirement for technical expertise. Entrepreneurs spend excessive time fundraising & need for more seedstage nance. Generalist platforms lack credibility. or specialist knowledge Crowdfunding expertise blended with a life science grounding is limited, and the existing platforms, VC’s or Business Angel networks are simply not scalable
Pilar Puig Head Life Science Analyst & BEN Leader
1m in
Based on an exclusive & scalable system of expert investment analysis.
Capital Cell generates revenue from charging campaign fees as a % of total funds raised through the platform. In addition, as traction is gained in the UK, we expect to charge a campaign set-up fee payable regardless of the campaigns success plus carry income locked in by way of campaign agreements. Capital Cell is also growing the BioExpert Network which is a community of life science experts who analyse and provide feedback on all potential campaigns. This makes Capital Cell unique as we provide real “value add” to the entrepreneur bringing the campaign and we have plans to monetise this network.
WHAT NEXT
Forecast P&L
In the process of creating Capital Cell Australia/Asia in partnership with local capital group ces by end of 2017
2017
2018
2019
2020
2021
Revenue Campaign fees - cash Carry income Campaign set-up fees Expert network fees Total revenue
630.000
1.890.000
3.937.500
7.425.000
-
-
-
-
-
56.700
94.500
162.000
239.400
8.100 14.400 652.500
100.800
351.000
798.000
1.824.000
4.383.000
8.385.000
14.033.400
(176.400)
(529.200)
Gross profit
476.100
1.518.300
73%
11.970.000
2.047.500
Cost of sales
GP%
Launching in the UK market with FCA authorisation at end of April
Expecting headcount of 17 in Cambridge + Barcelona o INVEST HERE http://www.capitalcell.net/investment/capital-cell-uk75/ First UK campaigns already actively pitching
FORECAST FINANCIAL DATA
(1.102.500) 3.280.500
(2.079.000) 6.306.000
(3.351.600) 10.681.800
74%
75%
75%
76%
(1.000.771)
(1.344.785)
(1.739.117)
(2.007.478)
Overheads Staff Technology
(505.628) (72.500)
(74.750)
(97.175)
(126.328)
(164.226)
External services
(144.000)
(204.800)
(287.760)
(403.312)
(566.974)
General & admin
(129.586)
(182.892)
(217.783)
(271.816)
Total overheads
(851.713) (1.463.213) (1.947.503) (2.540.573)
EBITDA
(375.613)
EBITDA %
-79%
55.087 4%
1.332.997 41%
3.765.427 60%
(308.524) (3.047.202) 7.634.598 71%
